Biological Phosphocalcic Metabolism and Coronary Artery Calcifications

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

83 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study a sample of patients in primary prevention, moderate cardiovascular risk (n = 83 patients), with normal, non-diabetic renal function. The investigators quantify the phophocalcic intake and excretion, realizing a food examination and a urine collection of 24 particular. The investigators will measure plasma levels of FGF23 serum calcium, phosphatemia, the investigators will calculate the tubular reabsorption of phosphate. The investigators will conduct a quantitative assessment of coronary calcification by a non-injected CT scan, measuring semi automated way Agatston calcium score. There will be an analysis of collinearity. An adjustment will be made for confounding variables in a generalized linear regression model.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of New Biomarkers for the Prediction of Cardiovascular Events

NCT04809506

Cardiovascular Diseases

RECRUITING

Evaluation of Cascade Screening for Elevated Lipoprotein(a)

NCT06157983

Cardiovascular Diseases Dyslipidemias Hereditary Diseases

ACTIVE_NOT_RECRUITING

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

NCT06122961

Cardiovascular Risk Heart Failure Chronic Kidney Disease

COMPLETED

Cardiovascular Risk Factors, Lipid Metabolism and Oxidative Stress

NCT01213303

Cardiovascular Disease

UNKNOWN

PREdisposition Genetical in Cardiac Insufficiency = Genetic Predisposition to Heart Failure

NCT01113268

ST Elevation (STEMI) Myocardial Infarction of Other Sites

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient

patient with cardiovascular risk (moderate)

24 h urines analyses

Intervention Type OTHER

patient collects urines during 24h

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

24 h urines analyses

patient collects urines during 24h

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalization for a cardiovascular check in the Detection Centre and the Atherosclerosis Prevention (CHU Rangueil Toulouse)
* In primary prevention of coronary heart disease
* Introducing an intermediate cardiovascular risk according to the European SCORE equation, that is to say, a risk of cardiovascular death at 10 years greater than or equal to 1% and less than 5%
* signed the informed consent,

Exclusion Criteria

* Chronic renal failure patients with an estimated GFR less than 60 mL / min / 1.73m2, due to alterations in phosphate metabolism,
* Patients receiving glucose-lowering therapy,
* Patients with a fasting blood glucose greater capillary or equal to 1.10 g / l, confirmed by a plasma glucose greater than or equal to 1.10g / l.
* The diuretic therapy patients (due to a change in urinary electrolytes)
* HIV-positive patients for HIV, antiretroviral (due to a change in urinary electrolytes)
* Pregnant women,
* Patients under judicial protection, guardianship or trusteeship.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No